← Back to home

UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER

Clinical trials for UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER trials appear

Sign up with your email to follow new studies for UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Blood test may forecast breast cancer drug response before surgery

Knowledge-focused Completed

This study is testing whether certain markers in the blood can predict how well the drug trastuzumab shrinks tumors in women with early HER2-positive breast cancer. Participants receive trastuzumab before breast-conserving surgery, and researchers compare blood marker levels with…

Matched conditions: UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER

Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused

Last updated Aug 18, 2026 05:00 UTC

UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER

Get alerted when new UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER trials appear

Blood test may forecast breast cancer drug response before surgery